Sabra Health Care REIT posts Q4 2025 net income of USD 27.23 million; same property managed senior housing Cash NOI up 12.6 percent

Reuters
02/13
Sabra Health Care REIT posts Q4 2025 net income of USD 27.23 million; same property managed senior housing Cash NOI up 12.6 percent

Sabra Health Care REIT Inc. reported its fourth quarter (Q4) 2025 earnings, posting net income per diluted common share of USD 0.11. Funds from Operations (FFO) and Normalized FFO per diluted common share were both USD 0.36, while Adjusted Funds from Operations (AFFO) per diluted common share stood at USD 0.37 and Normalized AFFO at USD 0.38 for the period. Net income attributable to shareholders for Q4 2025 was USD 27.23 million. For the full year (FY) 2025, net income attributable to shareholders reached USD 155.61 million, with net income per diluted common share at USD 0.64. Key business highlights for the quarter included a 12.6% year-over-year increase in same property managed senior housing Cash NOI for Q4 2025. The average quarterly year-over-year increase for 2025 was 15.0%, which includes the impact of stabilized facilities formerly operated by Holiday. EBITDARM coverage ratios for the quarter were as follows: Skilled Nursing/Transitional Care at 2.38x, Senior Housing - Leased at 1.52x, and Behavioral Health, Specialty Hospitals and Other at 3.99x.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sabra Health Care REIT Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212530499) on February 12, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10